Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying breast cancer patients who have a positive sentinel lymph node after receiving neoadjuvant systemic treatment. The trial evaluates whether axillary radiotherapy ART reduces the risk of lymphedema compared to axillary lymph node dissection ALND in these patients. The study also examines recurrence and overall survival rates, as well as quality of life. This is a prospective, randomized, open-label, parallel group, multicenter study involving approximately 820 patients over 5 years. Participants are divided into two groups one receives axillary radiotherapy without lymphadenectomy, including radiation to levels I and II axilla, level III, supraclavicular area, and possibly the internal mammary chain the other group undergoes axillary lymph node dissection plus radiotherapy to level III, supraclavicular area, and possibly the internal mammary chain. Patients are stratified by neoadjuvant treatment type chemotherapy or hormone therapy. A pilot phase with the first 200 patients has been completed, and interim analysis will be performed. During the study, participants undergo evaluations including imaging by ultrasound or MRI to assess axillary response after neoadjuvant therapy. Researchers will track disease-free survival up to 5 years, overall survival up to 5 years, and incidence of lymphedema up to 3 years after surgery. Quality of life and safety outcomes will also be monitored. The study aims to provide data on whether avoiding lymphadenectomy is a viable option for patients responding well to neoadjuvant treatment.
Actively Recruiting
Researchers are evaluating an interdisciplinary, community-based program called Reforat designed to reduce 30-day hospital readmissions and improve functional outcomes in patients aged 65 or older with chronic heart, lung, or mixed conditions after hospital discharge. The study aims to see if Reforat can lower readmission rates to 25% compared to standard care and improve medication adherence, quality of life, and survival. Patients will be compared between those receiving Reforat and those under usual care to assess health outcomes and cost-effectiveness. The intervention includes a full-scale program with interdisciplinary care, home follow-ups, therapeutic optimization, functional rehabilitation, health education, and psychosocial support. The trial also includes a feasibility phase and long-term follow-up. The intervention group receives presential follow-up by a multidisciplinary team, while the control group receives standard hospital-at-home care. Follow-up assessments occur at 3, 6, 9, and 12 months after discharge to monitor hospital readmissions, survival, nursing home admissions, and overall well-being. Participants will undergo assessments before and after the intervention, with a post-discharge evaluation at 30 days and continued monitoring up to 12 months. Researchers will collect data on readmissions, mortality, functional decline, medication adherence, risk of falls, social isolation, emotional well-being, and caregiver burden. Patient satisfaction and smoking cessation rates are also measured. This comprehensive evaluation aims to determine the programs impact on health outcomes and quality of life in older adults with chronic cardiorespiratory conditions.